Impel NeuroPharma (Nasdaq:IMPL) announced today that it changed its name to Impel Pharmaceuticals as part of a corporate rebrand.
Seattle-based Impel develops proprietary Precision Olfactory Delivery (POD) technology to treat patients suffering from diseases across a range of areas in addition to the central nervous system. The company’s Trudhesa nasal spray for treating migraine in adults received FDA approval in September 2021, and the company followed the regulatory nod with the pricing of a $45 million offering a week later.
According to a news release, the new name reflects the company’s ongoing corporate and strategic transformation as it marks the one-year anniversary of becoming a publicly-traded company.
Effective at market close today (April 25, 2022), the company will trade under its new name of Impel Pharmaceuticals while retaining the same IMPL ticker.
“The first-cycle approval and launch of Trudhesa using our proprietary POD technology reinforces the promise of the device to provide potential treatment options for multiple disease areas by delivering drugs into the vascular-rich upper nasal space,” Impel Chair and CEO Adrian Adams said in the release. “Now, as we celebrate our one-year anniversary as a publicly-traded company, changing our name to Impel Pharmaceuticals cements the company’s expanded corporate mission to provide transformative therapies for people suffering from diseases beyond the central nervous system.”
